NKTX reports third quarter financial results and clinical updates
Nkarta Inc. reported a third-quarter 2026 net loss of $33.3 million and announced plans to present initial clinical data for NKX019 at upcoming conferences, forecasting current cash to fund operations until 2029.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed